Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Dana Solutions","sponsor":"Curi Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curi Bio Acquires Dana Solutions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Dana Solutions"},{"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$146.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alkahest"},{"company":"Duke-NUS Medical School","sponsor":"A*STAR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Duke-NUS Medical School's Newly-Discovered Molecule Provides Dual Protection Against Vascular Inflammation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Duke-NUS Medical School"},{"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$45.0 million","newsHeadline":"Ionis Enters Exclusive Licensing Agreement with Bicycle Therapeutics Aimed at Further Advancing LICA Technology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bicycle Therapeutics"},{"company":"OliX Pharmaceutical","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$456.5 million","upfrontCash":"$6.5 million","newsHeadline":"Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"company":"Cardurion Pharmaceutical","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cardurion Pharmaceutical"},{"company":"Taisho Pharmaceutical","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Taisho Pharmaceutical"},{"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Flagship Pioneering Announce a Strategic Collaboration to Create a Portfolio of Transformational Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Flagship Pioneering"}]

Flagship Pioneering

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novo Nordisk and Flagship Pioneering Announce a Strategic Collaboration to Create a Portfolio of Transformational Medicines

Details:

Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.

Lead Product(s): Undisclosed

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Novo Nordisk

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 10, 2022

ASK
US

Upload
your Pipeline Activity

Taisho Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases

Details:

The partnership will leverage Elixirgen's proprietary ZSCAN4 therapy platform to advance treatments of aging-associated diseases. Elixirgen Therapeutics is currently performing a Phase I/II clinical trial using its ZSCAN4 therapy platform in disorders with bone marrow failure.

Lead Product(s): ZSCAN4-based Therapeutic

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Elixirgen Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 07, 2022

ASK
US

Upload
your Pipeline Activity

Cardurion Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

Details:

The investment will support the advancement of Cardurion’s pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program, and enable the Company to scale its team, and create an industry-leading platform.

Lead Product(s): Undisclosed

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bain Capital Life Sciences

Deal Size: $300.0 million Upfront Cash: Undisclosed

Deal Type: Financing October 27, 2021

ASK
US

Upload
your Pipeline Activity

OliX Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China

Details:

Through this agreement, OliX will use its GalNAc-asiRNA platform technology to discover lead compounds and secure development candidates for targets in cardiovascular, metabolic, and other diseases associated with the liver.

Lead Product(s): siRNA Therapeutics

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Hansoh Pharma

Deal Size: $456.5 million Upfront Cash: $6.5 million

Deal Type: Collaboration October 19, 2021

ASK
US

Upload
your Pipeline Activity

Bicycle Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ionis Enters Exclusive Licensing Agreement with Bicycle Therapeutics Aimed at Further Advancing LICA Technology

Details:

Under terms of the agreement, Ionis obtained an exclusive license to Bicycle's technology covering the entire class of transferrin receptor 1 Bicycles for use in targeted delivery of oligonucleotide drugs.

Lead Product(s): Undisclosed

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Ionis Pharmaceuticals

Deal Size: $45.0 million Upfront Cash: $45.0 million

Deal Type: Licensing Agreement July 13, 2021

ASK
US

Upload
your Pipeline Activity

Duke-NUS Medical School

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Virtual Booth

Digital Content

Duke-NUS Medical School's Newly-Discovered Molecule Provides Dual Protection Against Vascular Inflammation

Details:

A multidisciplinary team of researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research in Singapore discovered a new mitochondrial peptide called MOCCI that plays an important role in regulating inflammation of blood vessel and immunity.

Lead Product(s): Undisclosed

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Peptide

Partner/Sponsor/Collaborator: A*STAR

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2021

ASK
US

Upload
your Pipeline Activity

Alkahest

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human...

Details:

Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .

Lead Product(s): Plasma-based therapies

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Grifols International

Deal Size: $146.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 07, 2020

ASK
US

Upload
your Pipeline Activity

Dana Solutions

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Curi Bio Acquires Dana Solutions

Details:

Through the acquisition, Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn™, a deep learning platform for modeling cell and tissue phenotypes; Pulse™, an automated platform for contractility analysis of beating cardiomyocytes; and PhenoTox™.

Lead Product(s): Human iPSC-derived cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Curi Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY